Editorial

Rocky II, Rambo II, and the ACURATE neo2

EuroIntervention 2023;18:949-951. DOI: 10.4244/EIJ-E-22-00050

Patrick Serruys
Patrick W. Serruys1,2,3, MD, PhD; Ahmed Elkoumy1,2, MD; Scot Garg4, MD, PhD
1. Department of Cardiology, University of Galway, Galway, Ireland; 2. Corrib Core Lab, University of Galway, Galway, Ireland; 3. CÚRAM, SFI Research Centre for Medical Devices, Galway, Ireland; 4. Department of Cardiology, Royal Blackburn Hospital, Blackburn, UK
These iconic movie characters share one common trait with the ACURATE neo2 (Neo2): resilience − the ability to become stronger, better, and more successful − even after a setback.

In the randomised SCOPE I trial1, the self-expanding (SE) ACURATE neo (Neo; Boston Scientific) failed to meet non-inferiority against the balloon-expandable (BE) SAPIEN 3 (S3; Edwards Lifesciences) due to significant paravalvular leak (PVL). In SCOPE II2, the Neo failed against the CoreValve Evolut (Medtronic), with significantly higher rates of PVL and cardiac death at 30 days2. The causes of failure were targeted by adding 2 main features to the Neo: a newly designed ...

Sign in to read and download the full article

Forgot your password?

No account yet?
Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

Read next article
What makes a plaque rupture? A simple answer seems too much to ask for

Latest news